{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:24:14Z","timestamp":1791919454680,"version":"4.3.4"},"reference-count":259,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Russian Science Foundation","award":["#22-24-00990"],"award-info":[{"award-number":["#22-24-00990"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Replication stress (RS) is a characteristic state of cancer cells as they tend to exchange precision of replication for fast proliferation and increased genomic instability. To overcome the consequences of improper replication control, malignant cells frequently inactivate parts of their DNA damage response (DDR) pathways (the ATM-CHK2-p53 pathway), while relying on other pathways which help to maintain replication fork stability (ATR-CHK1). This creates a dependency on the remaining DDR pathways, vulnerability to further destabilization of replication and synthetic lethality of DDR inhibitors with common oncogenic alterations such as mutations of TP53, RB1, ATM, amplifications of MYC, CCNE1 and others. The response to RS is normally limited by coordination of cell cycle, transcription and replication. Inhibition of WEE1 and PKMYT1 kinases, which prevent unscheduled mitosis entry, leads to fragility of under-replicated sites. Recent evidence also shows that inhibition of Cyclin-dependent kinases (CDKs), such as CDK4\/6, CDK2, CDK8\/19 and CDK12\/13 can contribute to RS through disruption of DNA repair and replication control. Here, we review the main causes of RS in cancers as well as main therapeutic targets\u2014ATR, CHK1, PARP and their inhibitors.<\/jats:p>","DOI":"10.3390\/ijms25021263","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T11:04:57Z","timestamp":1705662297000},"page":"1263","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8137-0625","authenticated-orcid":false,"given":"Alvina I.","family":"Khamidullina","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Oncobiology, Institute of Gene Biology, Russian Academy of Sciences, 34\/5 Vavilov Street, 119334 Moscow, Russia"},{"name":"Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, 34\/5 Vavilov Street, 119334 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2946-3257","authenticated-orcid":false,"given":"Yaroslav E.","family":"Abramenko","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Oncobiology, Institute of Gene Biology, Russian Academy of Sciences, 34\/5 Vavilov Street, 119334 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra V.","family":"Bruter","sequence":"additional","affiliation":[{"name":"Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, 34\/5 Vavilov Street, 119334 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9080-5683","authenticated-orcid":false,"given":"Victor V.","family":"Tatarskiy","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Oncobiology, Institute of Gene Biology, Russian Academy of Sciences, 34\/5 Vavilov Street, 119334 Moscow, Russia"},{"name":"Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, 34\/5 Vavilov Street, 119334 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrc3916","article-title":"Replication Stress and Cancer","volume":"15","author":"Gaillard","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.molcel.2022.05.004","article-title":"Hallmarks of DNA Replication Stress","volume":"82","author":"Saxena","year":"2022","journal-title":"Mol. Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1158\/2159-8290.CD-17-1461","article-title":"Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling into Place","volume":"8","author":"Kotsantis","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Pai, C.-C., and Kearsey, S.E. (2017). A Critical Balance: dNTPs and the Maintenance of Genome Stability. Genes, 8.","DOI":"10.3390\/genes8020057"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.1038\/s41467-019-13674-5","article-title":"Transcription-Mediated Organization of the Replication Initiation Program across Large Genes Sets Common Fragile Sites Genome-Wide","volume":"10","author":"Brison","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"zcad039","DOI":"10.1093\/narcan\/zcad039","article-title":"CDK2 Regulates Collapsed Replication Fork Repair in CCNE1-Amplified Ovarian Cancer Cells via Homologous Recombination","volume":"5","author":"Brown","year":"2023","journal-title":"NAR Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Myers, K., Gagou, M.E., Zuazua-Villar, P., Rodriguez, R., and Meuth, M. (2009). ATR and Chk1 Suppress a Caspase-3-Dependent Apoptotic Response Following DNA Replication Stress. PLoS Genet., 5.","DOI":"10.1371\/journal.pgen.1000324"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrg.2017.47","article-title":"Synthetic Lethality and Cancer","volume":"18","author":"Bailey","year":"2017","journal-title":"Nat. Rev. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Zhang, J., Chan, D.W., and Lin, S.-Y. (2022). Exploiting DNA Replication Stress as a Therapeutic Strategy for Breast Cancer. Biomedicines, 10.","DOI":"10.3390\/biomedicines10112775"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective Killing of ATM- or p53-Deficient Cancer Cells through Inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1541-7786.MCR-14-0240","article-title":"A Synthetic Lethal Screen Reveals Enhanced Sensitivity to ATR Inhibitor Treatment in Mantle Cell Lymphoma with ATM Loss-of-Function","volume":"13","author":"Menezes","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1158\/0008-5472.CAN-13-2541","article-title":"Genome-Wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1\/2 Inhibitor Sensitivity","volume":"74","author":"Bajrami","year":"2014","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"13474","DOI":"10.18632\/oncotarget.24414","article-title":"CDK8\/19 Inhibition Induces Premature G1\/S Transition and ATR-Dependent Cell Death in Prostate Cancer Cells","volume":"9","author":"Nakamura","year":"2018","journal-title":"Oncotarget"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e108599","DOI":"10.15252\/embj.2021108599","article-title":"CDK4\/6 Inhibitors Induce Replication Stress to Cause Long-Term Cell Cycle Withdrawal","volume":"41","author":"Crozier","year":"2022","journal-title":"EMBO J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1101\/gad.1508907","article-title":"Strength in Numbers: Preventing Rereplication via Multiple Mechanisms in Eukaryotic Cells","volume":"21","author":"Arias","year":"2007","journal-title":"Genes Dev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41594-023-00949-1","article-title":"Mistimed Origin Licensing and Activation Stabilize Common Fragile Sites under Tight DNA-Replication Checkpoint Activation","volume":"30","author":"Brison","year":"2023","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cell.2011.06.012","article-title":"Eukaryotic Origin-Dependent DNA Replication In Vitro Reveals Sequential Action of DDK and S-CDK Kinases","volume":"146","author":"Heller","year":"2011","journal-title":"Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41586-022-04698-x","article-title":"CDC7-Independent G1\/S Transition Revealed by Targeted Protein Degradation","volume":"605","author":"Suski","year":"2022","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"16810","DOI":"10.1038\/s41598-022-20769-5","article-title":"CDK4\/6 Initiates Rb Inactivation and CDK2 Activity Coordinates Cell-Cycle Commitment and G1\/S Transition","volume":"12","author":"Kim","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.tibs.2011.05.002","article-title":"How Dormant Origins Promote Complete Genome Replication","volume":"36","author":"Blow","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.molcel.2018.05.026","article-title":"DNA Replication Determines Timing of Mitosis by Restricting CDK1 and PLK1 Activation","volume":"71","author":"Lemmens","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0092-8674(00)81902-9","article-title":"Oncogenic Ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a","volume":"88","author":"Serrano","year":"1997","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"34759","DOI":"10.1074\/jbc.M606737200","article-title":"Ras Triggers Ataxia-Telangiectasia-Mutated and Rad-3-Related Activation and Apoptosis through Sustained Mitogenic Signaling","volume":"281","author":"Fikaris","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nature05327","article-title":"Oncogene-Induced Senescence Is a DNA Damage Response Triggered by DNA Hyper-Replication","volume":"444","author":"Fumagalli","year":"2006","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.celrep.2019.06.004","article-title":"Selective Killing of RAS-Malignant Tissues by Exploiting Oncogene-Induced DNA Damage","volume":"28","author":"Murcia","year":"2019","journal-title":"Cell Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.celrep.2013.03.004","article-title":"Suppression of Nucleotide Metabolism Underlies the Establishment and Maintenance of Oncogene-Induced Senescence","volume":"3","author":"Aird","year":"2013","journal-title":"Cell Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"108184","DOI":"10.1016\/j.celrep.2020.108184","article-title":"SFPQ Depletion Is Synthetically Lethal with BRAFV600E in Colorectal Cancer Cells","volume":"32","author":"Klinger","year":"2020","journal-title":"Cell Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"13087","DOI":"10.1038\/ncomms13087","article-title":"Increased Global Transcription Activity as a Mechanism of Replication Stress in Cancer","volume":"7","author":"Kotsantis","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_30","first-page":"vdab180","article-title":"Increased Replication Stress and R-Loop Accumulation in EGFRvIII-Expressing Glioblastoma Present New Therapeutic Opportunities","volume":"4","author":"Struve","year":"2022","journal-title":"Neurooncol. Adv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"10258","DOI":"10.1158\/0008-5472.CAN-06-2178","article-title":"Retinoblastoma Pathway Defects Show Differential Ability to Activate the Constitutive DNA Damage Response in Human Tumorigenesis","volume":"66","author":"Tort","year":"2006","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal","volume":"83","author":"Kundra","year":"2023","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/45836","article-title":"Deregulated Cyclin E Induces Chromosome Instability","volume":"401","author":"Spruck","year":"1999","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1534-5807(02)00258-7","article-title":"CP110, a Cell Cycle-Dependent CDK Substrate, Regulates Centrosome Duplication in Human Cells","volume":"3","author":"Chen","year":"2002","journal-title":"Dev. Cell"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Fagundes, R., and Teixeira, L.K. (2021). Cyclin E\/CDK2: DNA Replication, Replication Stress and Genomic Instability. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.774845"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1038\/onc.2012.387","article-title":"Increased Replication Initiation and Conflicts with Transcription Underlie Cyclin E-Induced Replication Stress","volume":"32","author":"Jones","year":"2013","journal-title":"Oncogene"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41389-020-00270-2","article-title":"Overexpression of Cyclin E1 or Cdc25A Leads to Replication Stress, Mitotic Aberrancies, and Increased Sensitivity to Replication Checkpoint Inhibitors","volume":"9","author":"Kok","year":"2020","journal-title":"Oncogenesis"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10549-011-1638-4","article-title":"Targeting Low Molecular Weight Cyclin E (LMW-E) in Breast Cancer","volume":"132","author":"Jabbour","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.1038\/s41388-022-02527-z","article-title":"Low-Molecular-Weight Cyclin E Deregulates DNA Replication and Damage Repair to Promote Genomic Instability in Breast Cancer","volume":"41","author":"Li","year":"2022","journal-title":"Oncogene"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1158\/0008-5472.CAN-03-3672","article-title":"Tumor-Specific Low Molecular Weight Forms of Cyclin E Induce Genomic Instability and Resistance to p21, p27, and Antiestrogens in Breast Cancer","volume":"64","author":"Akli","year":"2004","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1101\/gad.11.11.1464","article-title":"Cyclin E-CDK2 Is a Regulator of p27Kip1","volume":"11","author":"Sheaff","year":"1997","journal-title":"Genes Dev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6594","DOI":"10.1158\/1078-0432.CCR-18-1446","article-title":"Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition","volume":"24","author":"Chen","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Chen, X., Yang, D., Carey, J.P.W., Karakas, C., Albarracin, C., Sahin, A.A., Arun, B.K., Guray Durak, M., Li, M., and Kohansal, M. (2021). Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration. Cancers, 13.","DOI":"10.3390\/cancers13071656"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41586-022-04638-9","article-title":"CCNE1 Amplification Is Synthetic Lethal with PKMYT1 Kinase Inhibition","volume":"604","author":"Gallo","year":"2022","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1038\/s41467-021-25904-w","article-title":"A Replication Stress Biomarker Is Associated with Response to Gemcitabine versus Combined Gemcitabine and ATR Inhibitor Therapy in Ovarian Cancer","volume":"12","author":"Konstantinopoulos","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1038\/s41467-018-07552-9","article-title":"Cyclin A2\/E1 Activation Defines a Hepatocellular Carcinoma Subclass with a Rearrangement Signature of Replication Stress","volume":"9","author":"Bayard","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Sailo, B.L., Banik, K., Girisa, S., Bordoloi, D., Fan, L., Halim, C.E., Wang, H., Kumar, A.P., Zheng, D., and Mao, X. (2019). FBXW7 in Cancer: What Has Been Unraveled Thus Far?. Cancers, 11.","DOI":"10.3390\/cancers11020246"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cell.2012.08.033","article-title":"C-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells","volume":"151","author":"Nie","year":"2012","journal-title":"Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1128\/MMBR.00030-06","article-title":"Replication Fork Stalling at Natural Impediments","volume":"71","year":"2007","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.molcel.2019.01.024","article-title":"R-Loops as Cellular Regulators and Genomic Threats","volume":"73","author":"Crossley","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jsb.2014.10.001","article-title":"Separation of Replication and Transcription Domains in Nucleoli","volume":"188","author":"Smirnov","year":"2014","journal-title":"J. Struct. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6683","DOI":"10.1093\/nar\/gky476","article-title":"Genome-Wide Analysis of the Spatiotemporal Regulation of Firing and Dormant Replication Origins in Human Cells","volume":"46","author":"Sugimoto","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.cell.2005.09.044","article-title":"Structure of the Rb C-Terminal Domain Bound to E2F1-DP1: A Mechanism for Phosphorylation-Induced E2F Release","volume":"123","author":"Rubin","year":"2005","journal-title":"Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1101\/gad.189837.112","article-title":"Structures of Inactive Retinoblastoma Protein Reveal Multiple Mechanisms for Cell Cycle Control","volume":"26","author":"Burke","year":"2012","journal-title":"Genes Dev."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Doan, A., Arand, J., Gong, D., Drainas, A.P., Shue, Y.T., Lee, M.C., Zhang, S., Walter, D.M., Chaikovsky, A.C., and Feldser, D.M. (2021). RB Depletion Is Required for the Continuous Growth of Tumors Initiated by Loss of RB. PLoS Genet., 17.","DOI":"10.1371\/journal.pgen.1009941"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"(2012). Cancer Genome Atlas Network Comprehensive Molecular Portraits of Human Breast Tumours. Nature, 490, 61\u201370.","DOI":"10.1038\/nature11412"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative Clinical Genomics of Advanced Prostate Cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1080\/15384101.2017.1338984","article-title":"Disruption of CDK-Resistant Chromatin Association by pRB Causes DNA Damage, Mitotic Errors, and Reduces Condensin II Recruitment","volume":"16","author":"Ishak","year":"2017","journal-title":"Cell Cycle"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7667","DOI":"10.1128\/MCB.00045-06","article-title":"Distinct Action of the Retinoblastoma Pathway on the DNA Replication Machinery Defines Specific Roles for Cyclin-Dependent Kinase Complexes in Prereplication Complex Assembly and S-Phase Progression","volume":"26","author":"Braden","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1080\/15384101.2020.1801190","article-title":"The E2F1 Transcription Factor and RB Tumor Suppressor Moonlight as DNA Repair Factors","volume":"19","author":"Manickavinayaham","year":"2020","journal-title":"Cell Cycle"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.molcel.2019.01.004","article-title":"A Code of Mono-Phosphorylation Modulates the Function of RB","volume":"73","author":"Sanidas","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.cell.2011.03.044","article-title":"Nucleotide Deficiency Promotes Genomic Instability in Early Stages of Cancer Development","volume":"145","author":"Bester","year":"2011","journal-title":"Cell"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Zamalloa, L.G., Pruitt, M.M., Hermance, N.M., Gali, H., Flynn, R.L., and Manning, A.L. (2023). RB Loss Sensitizes Cells to Replication-Associated DNA Damage after PARP Inhibition by Trapping. Life Sci. Alliance, 6.","DOI":"10.1101\/2023.03.25.532215"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"107669","DOI":"10.1016\/j.celrep.2020.107669","article-title":"Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress","volume":"31","author":"Nyquist","year":"2020","journal-title":"Cell Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"111475","DOI":"10.1016\/j.celrep.2022.111475","article-title":"A Mechanical G2 Checkpoint Controls Epithelial Cell Division through E-Cadherin-Mediated Regulation of Wee1-Cdk1","volume":"41","author":"Donker","year":"2022","journal-title":"Cell Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"110305","DOI":"10.1016\/j.celrep.2022.110305","article-title":"Compartmentalized Control of Cdk1 Drives Mitotic Spindle Assembly","volume":"38","author":"Serpico","year":"2022","journal-title":"Cell Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"16978","DOI":"10.1074\/jbc.M109.096552","article-title":"Cdc25 Phosphatases Are Required for Timely Assembly of CDK1-Cyclin B at the G2\/M Transition","volume":"285","author":"Timofeev","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1128\/MCB.00412-12","article-title":"Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption","volume":"32","author":"Beck","year":"2012","journal-title":"Mol. Cell. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"23891","DOI":"10.1073\/pnas.1915108116","article-title":"WEE1 Kinase Inhibitor AZD1775 Induces CDK1 Kinase-Dependent Origin Firing in Unperturbed G1- and S-Phase Cells","volume":"116","author":"Moiseeva","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"110261","DOI":"10.1016\/j.celrep.2021.110261","article-title":"WEE1 Kinase Protects the Stability of Stalled DNA Replication Forks by Limiting CDK2 Activity","volume":"38","author":"Petrosius","year":"2022","journal-title":"Cell Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1017\/erm.2020.3","article-title":"DNA Damage Checkpoint Kinases in Cancer","volume":"22","author":"Smith","year":"2020","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"The DNA Damage Response: Making It Safe to Play with Knives","volume":"40","author":"Ciccia","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.canlet.2020.09.016","article-title":"Reality CHEK: Understanding the Biology and Clinical Potential of CHK1","volume":"497","author":"Bhattacharya","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/ijc.28226","article-title":"Roles of Chk1 in Cell Biology and Cancer Therapy","volume":"134","author":"Zhang","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1016\/j.febslet.2012.09.048","article-title":"DNA Damage-Induced CHK1 Autophosphorylation at Ser296 Is Regulated by an Intramolecular Mechanism","volume":"586","author":"Okita","year":"2012","journal-title":"FEBS Lett."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.molcel.2015.07.029","article-title":"Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase","volume":"59","author":"Buisson","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41388-021-02080-1","article-title":"CHK1 Inhibition Exacerbates Replication Stress Induced by IGF Blockade","volume":"41","author":"Wu","year":"2022","journal-title":"Oncogene"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.dnarep.2008.03.017","article-title":"Poly(ADP-Ribose) Polymerase-1 Modulates DNA Repair Capacity and Prevents Formation of DNA Double Strand Breaks","volume":"7","author":"Woodhouse","year":"2008","journal-title":"DNA Repair"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1093\/nar\/gkl840","article-title":"PARP-1 and Ku Compete for Repair of DNA Double Strand Breaks by Distinct NHEJ Pathways","volume":"34","author":"Wang","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Howard, S.M., Yanez, D.A., and Stark, J.M. (2015). DNA Damage Response Factors from Diverse Pathways, Including DNA Crosslink Repair, Mediate Alternative End Joining. PLoS Genet., 11.","DOI":"10.1371\/journal.pgen.1004943"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA Repair Defect in BRCA Mutant Cells as a Therapeutic Strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1038\/s41467-019-10741-9","article-title":"Poly(ADP-Ribose) Polymerase-1 Antagonizes DNA Resection at Double-Strand Breaks","volume":"10","author":"Caron","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Gralewska, P., Gajek, A., Rybaczek, D., Marczak, A., and Rogalska, A. (2022). The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous BRCAMUT and BRCAWT Ovarian Cancer Cells. Cells, 11.","DOI":"10.3390\/cells11121889"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","article-title":"Cell Cycle Regulation: p53-p21-RB Signaling","volume":"29","author":"Engeland","year":"2022","journal-title":"Cell Death Differ."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.277.5331.1501","article-title":"Mitotic and G2 Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216","volume":"277","author":"Peng","year":"1997","journal-title":"Science"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1073\/pnas.96.7.3706","article-title":"GADD45 Induction of a G2\/M Cell Cycle Checkpoint","volume":"96","author":"Wang","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.cell.2022.12.036","article-title":"Cyclin E-Induced Replicative Stress Drives p53-Dependent Whole-Genome Duplication","volume":"186","author":"Zeng","year":"2023","journal-title":"Cell"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/sj.embor.7400587","article-title":"p53 Modulates Homologous Recombination by Transcriptional Regulation of the RAD51 Gene","volume":"7","author":"Kerr","year":"2006","journal-title":"EMBO Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e2113233119","DOI":"10.1073\/pnas.2113233119","article-title":"Rapid Recruitment of p53 to DNA Damage Sites Directs DNA Repair Choice and Integrity","volume":"119","author":"Wang","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1093\/nar\/gkw015","article-title":"p53 Coordinates Base Excision Repair to Prevent Genomic Instability","volume":"44","author":"Poletto","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.celrep.2016.03.011","article-title":"p53 Maintains Genomic Stability by Preventing Interference between Transcription and Replication","volume":"15","author":"Yeo","year":"2016","journal-title":"Cell Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"E4311","DOI":"10.1073\/pnas.1605828113","article-title":"DNA Damage Tolerance Pathway Involving DNA Polymerase \u03b9 and the Tumor Suppressor p53 Regulates DNA Replication Fork Progression","volume":"113","author":"Hampp","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e31723","DOI":"10.7554\/eLife.31723","article-title":"p53 Orchestrates DNA Replication Restart Homeostasis by Suppressing Mutagenic RAD52 and POL\u03b8 Pathways","volume":"7","author":"Roy","year":"2018","journal-title":"eLife"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.celrep.2016.10.036","article-title":"p53 Activity Results in DNA Replication Fork Processivity","volume":"17","author":"Klusmann","year":"2016","journal-title":"Cell Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"10274","DOI":"10.1158\/0008-5472.CAN-06-1527","article-title":"Nongenotoxic p53 Activation Protects Cells against S-Phase-Specific Chemotherapy","volume":"66","author":"Kranz","year":"2006","journal-title":"Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"32339","DOI":"10.18632\/oncotarget.5891","article-title":"Mdm2 Inhibition Confers Protection of p53-Proficient Cells from the Cytotoxic Effects of Wee1 Inhibitors","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1038\/s41388-022-02291-0","article-title":"Oncogenic RAS Sensitizes Cells to Drug-Induced Replication Stress via Transcriptional Silencing of P53","volume":"41","author":"Segeren","year":"2022","journal-title":"Oncogene"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and Consequences of Replication Stress","volume":"16","author":"Zeman","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"9693","DOI":"10.1158\/0008-5472.CAN-10-2286","article-title":"Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner","volume":"70","author":"Gilad","year":"2010","journal-title":"Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"107518","DOI":"10.1016\/j.pharmthera.2020.107518","article-title":"Discovery of ATR Kinase Inhibitor Berzosertib (VX-970, M6620): Clinical Candidate for Cancer Therapy","volume":"210","author":"Gorecki","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1200\/JCO.19.02404","article-title":"Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination with Carboplatin in Patients with Advanced Solid Tumors","volume":"38","author":"Yap","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","article-title":"Phase 1 Study of the ATR Inhibitor Berzosertib (formerly M6620, VX-970) Combined with Gemcitabine \u00b1 Cisplatin in Patients with Advanced Solid Tumours","volume":"125","author":"Middleton","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s41416-021-01406-w","article-title":"Phase 1 Study of the ATR Inhibitor Berzosertib in Combination with Cisplatin in Patients with Advanced Solid Tumours","volume":"125","author":"Shapiro","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1158\/1535-7163.MCT-21-0305","article-title":"ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non-Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts","volume":"20","author":"Baschnagel","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ccell.2021.02.014","article-title":"Therapeutic Targeting of ATR Yields Durable Regressions in Small Cell Lung Cancers with High Replication Stress","volume":"39","author":"Thomas","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctarc.2018.04.001","article-title":"Remarkable Response to a Novel ATR Inhibitor in a Patient with Poorly Differentiated Neuroendocrine Carcinoma","volume":"16","author":"Saito","year":"2018","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","article-title":"Berzosertib plus Gemcitabine versus Gemcitabine Alone in Platinum-Resistant High-Grade Serous Ovarian Cancer: A Multicentre, Open-Label, Randomised, Phase 2 Trial","volume":"21","author":"Konstantinopoulos","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2021.11.011","article-title":"A Phase 1b Study Evaluating the Safety and Preliminary Efficacy of Berzosertib in Combination with Gemcitabine in Patients with Advanced Non-Small Cell Lung Cancer","volume":"163","author":"Plummer","year":"2022","journal-title":"Lung Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"13837","DOI":"10.1038\/ncomms13837","article-title":"ATR Inhibitors as a Synthetic Lethal Therapy for Tumours Deficient in ARID1A","volume":"7","author":"Williamson","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.stem.2018.09.016","article-title":"A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening","volume":"23","author":"Yan","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1021\/jm301859s","article-title":"Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-Yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-Yl}-1H-Indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity","volume":"56","author":"Foote","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.3892\/or.2017.5580","article-title":"Inhibition of ATR Potentiates the Cytotoxic Effect of Gemcitabine on Pancreatic Cancer Cells through Enhancement of DNA Damage and Abrogation of Ribonucleotide Reductase Induction by Gemcitabine","volume":"37","author":"Liu","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"41950","DOI":"10.1038\/srep41950","article-title":"Mechanisms Responsible for the Synergistic Antileukemic Interactions between ATR Inhibition and Cytarabine in Acute Myeloid Leukemia Cells","volume":"7","author":"Ma","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Jones, C.D., Blades, K., Foote, K.M., Guichard, S.M., Jewsbury, P.J., McGuire, T., Nissink, J.W., Odedra, R., Tam, K., and Thommes, P. (2013). Abstract 2348: Discovery of AZD6738, a Potent and Selective Inhibitor with the Potential to Test the Clinical Efficacy of ATR Kinase Inhibition in Cancer Patients. Cancer Res., 73.","DOI":"10.1158\/1538-7445.AM2013-2348"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","article-title":"Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent","volume":"61","author":"Foote","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"44289","DOI":"10.18632\/oncotarget.6247","article-title":"The Orally Active and Bioavailable ATR Kinase Inhibitor AZD6738 Potentiates the Anti-Tumor Effects of Cisplatin to Resolve ATM-Deficient Non-Small Cell Lung Cancer in Vivo","volume":"6","author":"Vendetti","year":"2015","journal-title":"Oncotarget"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.radonc.2017.06.025","article-title":"Inhibition of Ataxia Telangiectasia Related-3 (ATR) Improves Therapeutic Index in Preclinical Models of Non-Small Cell Lung Cancer (NSCLC) Radiotherapy","volume":"124","author":"Dunne","year":"2017","journal-title":"Radiother. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/1535-7163.MCT-18-0010","article-title":"The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression","volume":"17","author":"Wallez","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.oraloncology.2019.05.028","article-title":"ATR Inhibition Sensitizes HPV\u2212 and HPV+ Head and Neck Squamous Cell Carcinoma to Cisplatin","volume":"95","author":"Leonard","year":"2019","journal-title":"Oral Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Bristol, M.L., Das, D., and Morgan, I.M. (2017). Why Human Papillomaviruses Activate the DNA Damage Response (DDR) and How Cellular and Viral Replication Persists in the Presence of DDR Signaling. Viruses, 9.","DOI":"10.3390\/v9100268"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/ijc.30373","article-title":"Anti-Tumor Activity of the ATR Inhibitor AZD6738 in HER2 Positive Breast Cancer Cells","volume":"140","author":"Kim","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-21-2997","article-title":"ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib","volume":"82","author":"Wilson","year":"2022","journal-title":"Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/s41416-020-1016-2","article-title":"Complete Loss of ATM Function Augments Replication Catastrophe Induced by ATR Inhibition and Gemcitabine in Pancreatic Cancer Models","volume":"123","author":"Dunlop","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/s41416-018-0017-x","article-title":"From Checkpoint to Checkpoint: DNA Damage ATR\/Chk1 Checkpoint Signalling Elicits PD-L1 Immune Checkpoint Activation","volume":"118","author":"Mouw","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA Double-Strand Break Repair Pathway Regulates PD-L1 Expression in Cancer Cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models","volume":"19","author":"Wengner","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"6813","DOI":"10.1038\/s41467-021-27057-2","article-title":"ATR Inhibition Enables Complete Tumour Regression in ALK-Driven NB Mouse Models","volume":"12","author":"Szydzik","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2022.11.014","article-title":"Elimusertib (BAY1895344), a Novel ATR Inhibitor, Demonstrates in Vivo Activity in ATRX Mutated Models of Uterine Leiomyosarcoma","volume":"168","author":"Harold","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ygyno.2022.12.003","article-title":"Ovarian and Uterine Carcinosarcomas Are Sensitive in Vitro and in Vivo to Elimusertib, a Novel Ataxia-Telangiectasia and Rad3-Related (ATR) Kinase Inhibitor","volume":"169","author":"Manavella","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_130","first-page":"161","article-title":"Combined Inhibition of PARP and ATR Synergistically Potentiates the Antitumor Activity of HER2-Targeting Antibody-Drug Conjugate in HER2-Positive Cancers","volume":"13","author":"Li","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-21-1010","article-title":"ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer","volume":"27","author":"Tang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","article-title":"Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells with Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents","volume":"20","author":"Jo","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e156087","DOI":"10.1172\/jci.insight.156087","article-title":"ATR Represents a Therapeutic Vulnerability in Clear Cell Renal Cell Carcinoma","volume":"7","author":"Seidel","year":"2022","journal-title":"JCI Insight"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1158\/1535-7163.MCT-22-0685","article-title":"Selective Inhibition of ATM-Dependent Double-Strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors","volume":"22","author":"Turchick","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","article-title":"Camonsertib in DNA Damage Response-Deficient Advanced Solid Tumors: Phase 1 Trial Results","volume":"29","author":"Yap","year":"2023","journal-title":"Nat. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1535-7163.MCT-21-0615","article-title":"RP-3500: A Novel, Potent, and Selective ATR Inhibitor That Is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors","volume":"21","author":"Roulston","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1158\/1535-7163.MCT-18-0919","article-title":"DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas","volume":"18","author":"Restelli","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1158\/0008-5472.CAN-18-2480","article-title":"Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress","volume":"79","author":"Young","year":"2019","journal-title":"Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","article-title":"Targeting the ATR\/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models","volume":"23","author":"Kim","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1101\/gad.290957.116","article-title":"ATR Inhibition Disrupts Rewired Homologous Recombination and Fork Protection Pathways in PARP Inhibitor-Resistant BRCA-Deficient Cancer Cells","volume":"31","author":"Yazinski","year":"2017","journal-title":"Genes Dev."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1158\/1078-0432.CCR-19-0448","article-title":"The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition","volume":"25","author":"Parmar","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Gralewska, P., Gajek, A., Marczak, A., Miku\u0142a, M., Ostrowski, J., \u015aliwi\u0144ska, A., and Rogalska, A. (2020). PARP Inhibition Increases the Reliance on ATR\/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249715"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR Inhibition Overcomes PARP Inhibitor and Platinum Resistance in Ovarian Cancer Models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"111678","DOI":"10.1016\/j.mrfmmm.2019.111678","article-title":"ATR Kinase Inhibition Sensitizes Quiescent Human Cells to the Lethal Effects of Cisplatin but Increases Mutagenesis","volume":"816\u2013818","author":"Hutcherson","year":"2019","journal-title":"Mutat. Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jamaoncol.2021.3441","article-title":"Effect of Cisplatin and Gemcitabine with or without Berzosertib in Patients with Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial","volume":"7","author":"Pal","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","article-title":"Phase I Study of ATR Inhibitor M6620 in Combination with Topotecan in Patients with Advanced Solid Tumors","volume":"36","author":"Thomas","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_147","first-page":"8518","article-title":"Targeting Genomic Instability in Extrapulmonary Small Cell Neuroendocrine Cancers: A Phase II Study with ATR Inhibitor Berzosertib and Topotecan","volume":"40","author":"Takahashi","year":"2022","journal-title":"J. Clin. Orthod."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1158\/1535-7163.MCT-14-1037","article-title":"LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms","volume":"14","author":"King","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00280-019-03950-y","article-title":"Prexasertib, a Checkpoint Kinase Inhibitor: From Preclinical Data to Clinical Development","volume":"85","author":"Angius","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"929123","DOI":"10.3389\/fonc.2022.929123","article-title":"Chromosome 11q Loss and MYCN Amplification Demonstrate Synthetic Lethality with Checkpoint Kinase 1 Inhibition in Neuroblastoma","volume":"12","author":"Keller","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1038\/s41388-020-1383-4","article-title":"Resistance to the CHK1 Inhibitor Prexasertib Involves Functionally Distinct CHK1 Activities in BRCA Wild-Type Ovarian Cancer","volume":"39","author":"Nair","year":"2020","journal-title":"Oncogene"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ygyno.2022.09.019","article-title":"A Phase 2 Study of Prexasertib (LY2606368) in Platinum Resistant or Refractory Recurrent Ovarian Cancer","volume":"167","author":"Konstantinopoulos","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1021\/acs.jmedchem.5b01938","article-title":"Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-Ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-Yl)amino)pyrazine-2-Carbonitrile (CCT245737)","volume":"59","author":"Osborne","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.18632\/oncotarget.4919","article-title":"The Clinical Development Candidate CCT245737 Is an Orally Active CHK1 Inhibitor with Preclinical Activity in RAS Mutant NSCLC and E\u00b5-MYC Driven B-Cell Lymphoma","volume":"7","author":"Walton","year":"2016","journal-title":"Oncotarget"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1158\/0008-5472.CAN-19-1372","article-title":"CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells","volume":"80","author":"Rogers","year":"2020","journal-title":"Cancer Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/aps.2016.136","article-title":"The Chk1 Inhibitor MK-8776 Increases the Radiosensitivity of Human Triple-Negative Breast Cancer by Inhibiting Autophagy","volume":"38","author":"Zhou","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1200\/JCO.2014.57.5027","article-title":"Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 as Monotherapy and in Combination with Gemcitabine in Patients with Advanced Solid Tumors","volume":"33","author":"Daud","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Cui, Q., Cai, C.-Y., Wang, J.-Q., Zhang, S., Gupta, P., Ji, N., Yang, Y., Dong, X., Yang, D.-H., and Chen, Z.-S. (2019). Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-Glycoprotein Overexpressing Cancer Cells. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174095"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"15069","DOI":"10.1021\/acs.jmedchem.1c00994","article-title":"Discovery and Development of a Potent, Selective, and Orally Bioavailable CHK1 Inhibitor Candidate: 5-((4-((3-Amino-3-Methylbutyl)amino)-5-(trifluoromethyl)pyrimidin-2-Yl)amino)picolinonitrile","volume":"64","author":"Jin","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41416-023-02279-x","article-title":"A Phase 1\/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Patients with Advanced Cancer","volume":"129","author":"Kristeleit","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"6723","DOI":"10.1158\/1078-0432.CCR-12-2442","article-title":"Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias","volume":"18","author":"Karp","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Martorana, F., Da Silva, L.A., Sessa, C., and Colombo, I. (2022). Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents. Cancers, 14.","DOI":"10.3390\/cancers14040953"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jamaoncol.2021.0006","article-title":"Olaparib Monotherapy for Previously Treated Pancreatic Cancer with DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials","volume":"7","author":"Javle","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_164","first-page":"5018","article-title":"BRCAAWAY: A Randomized Phase 2 Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with DNA Repair Defects","volume":"40","author":"Hussain","year":"2022","journal-title":"J. Clin. Orthod."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"17041","DOI":"10.1073\/pnas.1305170110","article-title":"Stabilization of Mutant BRCA1 Protein Confers PARP Inhibitor and Platinum Resistance","volume":"110","author":"Johnson","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature14328","article-title":"REV7 Counteracts DNA Double-Strand Break Resection and Affects PARP Inhibition","volume":"521","author":"Xu","year":"2015","journal-title":"Nature"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.cell.2018.03.050","article-title":"DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity","volume":"173","author":"Gupta","year":"2018","journal-title":"Cell"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1136\/ijgc-2020-001694","article-title":"DUETTE: A Phase II Randomized, Multicenter Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer, Who Have Previously Received poly(ADP-Ribose) Polymerase (PARP) Inhibitor Maintenance Treatment","volume":"30","author":"McMullen","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_169","first-page":"TPS619","article-title":"PARTNER: A Randomized, Phase II\/III Trial to Evaluate the Safety and Efficacy of the Addition of Olaparib to Platinum-Based Neoadjuvant Chemotherapy in Patients with Triple-Negative And\/or Germline BRCA-Mutated Breast Cancer","volume":"40","author":"Drewett","year":"2022","journal-title":"J. Clin. Orthod."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_171","first-page":"542","article-title":"Impact of the Combination of Durvalumab (MEDI4736) plus Olaparib (AZD2281) Administered prior to Surgery in the Molecular Profile of Resectable Urothelial Bladder Cancer: NEODURVARIB Trial","volume":"38","author":"Fernandez","year":"2020","journal-title":"J. Clin. Orthod."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1200\/PO.20.00247","article-title":"Clinical Efficacy of Olaparib in IDH1\/IDH2-Mutant Mesenchymal Sarcomas","volume":"5","author":"Eder","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"9930","DOI":"10.1038\/s41598-020-66018-5","article-title":"Antitumor Effect of a WEE1 Inhibitor and Potentiation of Olaparib Sensitivity by DNA Damage Response Modulation in Triple-Negative Breast Cancer","volume":"10","author":"Ha","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.ccell.2019.05.001","article-title":"Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity While Maintaining Efficacy","volume":"35","author":"Fang","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Gene Aberrations (TOPARP-B): A Multicentre, Open-Label, Randomised, Phase 2 Trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.19.02745","article-title":"Olaparib Versus Nonplatinum Chemotherapy in Patients with Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1\/2 Mutation (SOLO3): A Randomized Phase III Trial","volume":"38","author":"Penson","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1200\/JCO.21.01604","article-title":"Overall Survival Results from the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"40","author":"Kindler","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ijc.34525","article-title":"Olaparib Efficacy in Patients with Germline BRCA-Mutated, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses from the Phase III OlympiAD Trial","volume":"153","author":"Senkus","year":"2023","journal-title":"Int. J. Cancer"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.3802\/jgo.2022.33.e12","article-title":"A Single-Arm, Phase II Study of Niraparib and Bevacizumab Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer Patients Previously Treated with a PARP Inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)\/NIRVANA-R Trial","volume":"33","author":"Park","year":"2022","journal-title":"J. Gynecol. Oncol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","article-title":"Niraparib in Patients with Metastatic Castration-Resistant Prostate Cancer and DNA Repair Gene Defects (GALAHAD): A Multicentre, Open-Label, Phase 2 Trial","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_181","first-page":"TPS291","article-title":"A Phase II Single-Arm Trial of Niraparib in Platinum-Sensitive Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (PLATPARP)","volume":"41","author":"Narayan","year":"2023","journal-title":"J. Clin. Orthod."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"18654","DOI":"10.1002\/cam4.6475","article-title":"A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination with Everolimus in Advanced Ovarian and Breast Cancers","volume":"12","author":"Starks","year":"2023","journal-title":"Cancer Med."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/ijgc-2021-002933","article-title":"ATHENA (GOG-3020\/ENGOT-ov45): A Randomized, Phase III Trial to Evaluate Rucaparib as Monotherapy (ATHENA-MONO) and Rucaparib in Combination with Nivolumab (ATHENA-COMBO) as Maintenance Treatment Following Frontline Platinum-Based Chemotherapy in Ovarian Cancer","volume":"31","author":"Monk","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ejca.2021.09.028","article-title":"Rucaparib in Patients Presenting a Metastatic Breast Cancer with Homologous Recombination Deficiency, without Germline BRCA1\/2 Mutation","volume":"159","author":"Patsouris","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients with Newly Diagnosed Ovarian Cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or Physician\u2019s Choice in Metastatic Prostate Cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib Monotherapy in Metastatic Castration-Resistant Prostate Cancer with DNA Repair Alterations (TALAPRO-1): An Open-Label, Phase 2 Trial","volume":"22","author":"Mehra","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_188","first-page":"TPS1109","article-title":"A Phase II Clinical Trial of Talazoparib Monotherapy for PALB2 Mutation-Associated Advanced Breast Cancer","volume":"39","author":"Gruber","year":"2021","journal-title":"J. Clin. Orthod."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s43018-022-00439-1","article-title":"A Phase II Study of Talazoparib Monotherapy in Patients with Wild-Type BRCA1 and BRCA2 with a Mutation in Other Homologous Recombination Genes","volume":"3","author":"Gruber","year":"2022","journal-title":"Nat Cancer"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2022.5228","article-title":"Avelumab Plus Talazoparib in Patients with Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial","volume":"9","author":"Yap","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-020-00959-2","article-title":"A WEE1 Family Business: Regulation of Mitosis, Cancer Progression, and Therapeutic Target","volume":"13","author":"Cerchione","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1158\/1078-0432.CCR-19-3470","article-title":"Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)","volume":"26","author":"Cole","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1200\/JCO.2014.60.4009","article-title":"Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients with Refractory Solid Tumors","volume":"33","author":"Do","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1200\/JCO.2016.67.5942","article-title":"Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients with TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy within 3 Months","volume":"34","author":"Leijen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","article-title":"Adavosertib plus Gemcitabine for Platinum-Resistant or Platinum-Refractory Recurrent Ovarian Cancer: A Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial","volume":"397","author":"Lheureux","year":"2021","journal-title":"Lancet"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"S1035","DOI":"10.1016\/j.annonc.2020.08.1546","article-title":"1785P Phase Ib Expansion Study of Adavosertib plus Olaparib in Patients with Extensive-Stage or Relapsed Small Cell Lung Cancer","volume":"31","author":"Li","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/1535-7163.MCT-20-0252","article-title":"Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress","volume":"20","author":"Lindemann","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1158\/1078-0432.CCR-17-0947","article-title":"Replication Stress Leading to Apoptosis within the S-Phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation","volume":"23","author":"Tanaka","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/jnci\/djp017","article-title":"E6 and e7 Gene Silencing and Transformed Phenotype of Human Papillomavirus 16-Positive Oropharyngeal Cancer Cells","volume":"101","author":"Rampias","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/sj.bjc.6602665","article-title":"High-Level Expression of Rad51 Is an Independent Prognostic Marker of Survival in Non-Small-Cell Lung Cancer Patients","volume":"93","author":"Qiao","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1158\/1541-7786.MCR-18-0860","article-title":"Multiple Defects Sensitize p53-Deficient Head and Neck Cancer Cells to the WEE1 Kinase Inhibition","volume":"17","author":"Diab","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1158\/1078-0432.CCR-13-2858","article-title":"Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer","volume":"20","author":"Moser","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1074\/jbc.M114.624056","article-title":"Identification and Pharmacological Inactivation of the MYCN Gene Network as a Therapeutic Strategy for Neuroblastic Tumor Cells","volume":"290","author":"Chayka","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_204","first-page":"5259","article-title":"PKMYT1 Aggravates the Progression of Ovarian Cancer by Targeting SIRT3","volume":"24","author":"Xuan","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.celrep.2015.11.021","article-title":"Genome-Wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells","volume":"13","author":"Toledo","year":"2015","journal-title":"Cell Rep."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"zcad029","DOI":"10.1093\/narcan\/zcad029","article-title":"Synthetic Lethal Interaction between WEE1 and PKMYT1 Is a Target for Multiple Low-Dose Treatment of High-Grade Serous Ovarian Carcinoma","volume":"5","author":"Benada","year":"2023","journal-title":"NAR Cancer"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1038\/onc.2012.504","article-title":"The CDK1 Inhibitory Kinase MYT1 in DNA Damage Checkpoint Recovery","volume":"32","author":"Chow","year":"2013","journal-title":"Oncogene"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-20-0219","article-title":"A Biomarker-Enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-Sensitive TP53-Mutant Ovarian Cancer","volume":"26","author":"Oza","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1200\/JCO.20.03167","article-title":"Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma","volume":"39","author":"Liu","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.21.01435","article-title":"Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) with Active Monitoring","volume":"39","author":"Seligmann","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-21-0329","article-title":"Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-Daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors","volume":"27","author":"Takebe","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2022.08.006","article-title":"Patient Self-Reporting of Tolerability Using PRO-CTCAE in a Randomized Double-Blind, Placebo-Controlled Phase II Trial Comparing Gemcitabine in Combination with Adavosertib or Placebo in Patients with Platinum Resistant or Refractory Epithelial Ovarian Carcinoma","volume":"167","author":"Madariaga","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1002\/cncr.34786","article-title":"Pediatric Phase 2 Trial of a WEE1 Inhibitor, Adavosertib (AZD1775), and Irinotecan for Relapsed Neuroblastoma, Medulloblastoma, and Rhabdomyosarcoma","volume":"129","author":"Cole","year":"2023","journal-title":"Cancer"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygyno.2023.05.063","article-title":"WEE1 Inhibitor Adavosertib in Combination with Carboplatin in Advanced TP53 Mutated Ovarian Cancer: A Biomarker-Enriched Phase II Study","volume":"174","author":"Embaby","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1200\/JCO.22.00830","article-title":"Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification","volume":"41","author":"Fu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1200\/JCO.2016.67.5991","article-title":"Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination with Gemcitabine, Cisplatin, or Carboplatin in Patients with Advanced Solid Tumors","volume":"34","author":"Leijen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"7454","DOI":"10.1158\/1078-0432.CCR-17-0983","article-title":"Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach","volume":"23","author":"Li","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1158\/1078-0432.CCR-17-3796","article-title":"A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma","volume":"24","author":"Rodriguez","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1200\/JCO.19.00730","article-title":"Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination with Gemcitabine and Radiation for Patients with Locally Advanced Pancreatic Cancer","volume":"37","author":"Cuneo","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11523-020-00701-5","article-title":"Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study","volume":"15","author":"Kato","year":"2020","journal-title":"Target. Oncol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"e033009","DOI":"10.1136\/bmjopen-2019-033009","article-title":"Phase I Trial of WEE1 Inhibition with Chemotherapy and Radiotherapy as Adjuvant Treatment, and a Window of Opportunity Trial with Cisplatin in Patients with Head and Neck Cancer: The WISTERIA Trial Protocol","volume":"10","author":"Kong","year":"2020","journal-title":"BMJ Open"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00280-020-04101-4","article-title":"Effect of Food on the Pharmacokinetics of the WEE1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors","volume":"86","author":"So","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1002\/cncr.33789","article-title":"Phase 1 Trial of Adavosertib (AZD1775) in Combination with Concurrent Radiation and Cisplatin for Intermediate-Risk and High-Risk Head and Neck Squamous Cell Carcinoma","volume":"127","author":"Chera","year":"2021","journal-title":"Cancer"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1158\/1078-0432.CCR-20-3089","article-title":"Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer","volume":"27","author":"Keenan","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11523-023-00965-7","article-title":"A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors","volume":"18","author":"Bauer","year":"2023","journal-title":"Target. Oncol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10637-023-01371-6","article-title":"A Phase Ib Study of Adavosertib, a Selective Wee1 Inhibitor, in Patients with Locally Advanced or Metastatic Solid Tumors","volume":"41","author":"Falchook","year":"2023","journal-title":"Investig. New Drugs"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1136\/ijgc-2023-004491","article-title":"A Phase I Study of the Wee1 Kinase Inhibitor Adavosertib (AZD1775) in Combination with Chemoradiation in Cervical, Upper Vaginal, and Uterine Cancers","volume":"33","author":"Milosevic","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00280-023-04511-0","article-title":"Phase 1 Study of Belinostat and Adavosertib in Patients with Relapsed or Refractory Myeloid Malignancies","volume":"91","author":"Shafer","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_229","doi-asserted-by":"crossref","unstructured":"Malumbres, M. (2014). Cyclin-Dependent Kinases. Genome Biol., 15.","DOI":"10.1186\/gb4184"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell Cycle, CDKs and Cancer: A Changing Paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.molcel.2009.06.036","article-title":"Cdk1 Participates in BRCA1-Dependent S Phase Checkpoint Control in Response to DNA Damage","volume":"35","author":"Johnson","year":"2009","journal-title":"Mol. Cell"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm.2377","article-title":"Compromised CDK1 Activity Sensitizes BRCA-Proficient Cancers to PARP Inhibition","volume":"17","author":"Johnson","year":"2011","journal-title":"Nat. Med."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1158\/0008-5472.780.65.3","article-title":"Cdk Inhibition in Human Cells Compromises chk1 Function and Activates a DNA Damage Response","volume":"65","author":"Maude","year":"2005","journal-title":"Cancer Res."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer","volume":"381","author":"Im","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_235","doi-asserted-by":"crossref","unstructured":"Pandey, K., Katuwal, N.B., Park, N., Hur, J., Cho, Y.B., Kim, S.K., Lee, S.A., Kim, I., Lee, S.-R., and Moon, Y.W. (2022). Combination of Abemaciclib Following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2\/M Cell Cycle Phase. Cancers, 14.","DOI":"10.3390\/cancers14010210"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"7288","DOI":"10.1093\/nar\/gkad538","article-title":"CDK8 and CDK19: Positive Regulators of Signal-Induced Transcription and Negative Regulators of Mediator Complex Proteins","volume":"51","author":"Chen","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"8665","DOI":"10.1093\/nar\/gkab628","article-title":"Loss of Cyclin C or CDK8 Provides ATR Inhibitor Resistance by Suppressing Transcription-Associated Replication Stress","volume":"49","author":"Lloyd","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1038\/s41598-022-10188-x","article-title":"Aberrant R-Loop-Induced Replication Stress in MED12-Mutant Uterine Fibroids","volume":"12","author":"Muralimanoharan","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_239","doi-asserted-by":"crossref","unstructured":"Khamidullina, A.I., Yastrebova, M.A., Bruter, A.V., Nuzhina, J.V., Vorobyeva, N.E., Khrustaleva, A.M., Varlamova, E.A., Tyakht, A.V., Abramenko, Y.E., and Ivanova, E.S. (2023). CDK8\/19 Inhibition Attenuates G1 Arrest Induced by BCR-ABL Antagonists and Accelerates Death of Chronic Myelogenous Leukemia Cells. BioRxiv, 2023.09.25.559286.","DOI":"10.1101\/2023.09.25.559286"},{"key":"ref_240","doi-asserted-by":"crossref","unstructured":"K\u00f6hler, K., Sanchez-Pulido, L., H\u00f6fer, V., Marko, A., Ponting, C.P., Snijders, A.P., Feederle, R., Schepers, A., and Boos, D. (2019). The Cdk8\/19-Cyclin C Transcription Regulator Functions in Genome Replication through Metazoan Sld7. PLoS Biol., 17.","DOI":"10.1371\/journal.pbio.2006767"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.celrep.2016.03.030","article-title":"Identification of Mediator Kinase Substrates in Human Cells Using Cortistatin A and Quantitative Phosphoproteomics","volume":"15","author":"Poss","year":"2016","journal-title":"Cell Rep."},{"key":"ref_242","doi-asserted-by":"crossref","unstructured":"Chen, B., Wen, P., Hu, G., Gao, Y., Qi, X., Zhu, K., Chen, S., Wu, L., Xu, A., and Zhao, G. (2020). Antagonizing CDK8 Sensitizes Colorectal Cancer to Radiation Through Potentiating the Transcription of e2f1 Target Gene apaf1. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.00408"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1101\/gad.16962311","article-title":"The Cyclin K\/Cdk12 Complex Maintains Genomic Stability via Regulation of Expression of DNA Damage Response Genes","volume":"25","author":"Blazek","year":"2011","journal-title":"Genes Dev."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"e47592","DOI":"10.15252\/embr.201847592","article-title":"CDK12 Controls G1\/S Progression by Regulating RNAPII Processivity at Core DNA Replication Genes","volume":"20","author":"Pilarova","year":"2019","journal-title":"EMBO Rep."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41419-022-05347-x","article-title":"Overlapping Gene Dependencies for PARP Inhibitors and Carboplatin Response Identified by Functional CRISPR-Cas9 Screening in Ovarian Cancer","volume":"13","author":"Coelho","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_246","doi-asserted-by":"crossref","unstructured":"Ragupathi, A., Singh, M., Perez, A.M., and Zhang, D. (2023). Targeting the BRCA1\/2 Deficient Cancer with PARP Inhibitors: Clinical Outcomes and Mechanistic Insights. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1133472"},{"key":"ref_247","first-page":"3095","article-title":"BLU-222, an Oral, Potent, and Selective CDK2 Inhibitor, in Patients with Advanced Solid Tumors: Phase 1 Monotherapy Dose Escalation","volume":"41","author":"Patel","year":"2023","journal-title":"J. Clin. Orthod."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/1538-7445.AM2023-950","article-title":"Abstract 950: Targeting PKMYT1 Kinase Is an Effective Treatment Strategy in Triple Negative Breast Cancers with Low Molecular Weight Cyclin E (LMW-E) Expression","volume":"83","author":"Lulla","year":"2023","journal-title":"Cancer Res."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1158\/1078-0432.CCR-22-0875","article-title":"Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer","volume":"28","author":"Durinikova","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"e29065","DOI":"10.1002\/pbc.29065","article-title":"A Phase 1 Study of Prexasertib (LY2606368), a CHK1\/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors: A Report from the Children\u2019s Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515)","volume":"68","author":"Cash","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41523-020-00181-w","article-title":"Cyclin E Expression Is Associated with High Levels of Replication Stress in Triple-Negative Breast Cancer","volume":"6","author":"Jongeneel","year":"2020","journal-title":"NPJ Breast Cancer"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1158\/2767-9764.CRC-22-0168","article-title":"Replication Stress Defines Distinct Molecular Subtypes across Cancers","volume":"2","author":"Takahashi","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12967-023-03872-7","article-title":"A Machine Learning Framework Develops a DNA Replication Stress Model for Predicting Clinical Outcomes and Therapeutic Vulnerability in Primary Prostate Cancer","volume":"21","author":"Huang","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11912-021-01098-8","article-title":"WEE1 Inhibitor: Clinical Development","volume":"23","author":"Kong","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_256","doi-asserted-by":"crossref","unstructured":"Shkundina, I.S., Gall, A.A., Dick, A., Cocklin, S., and Mazin, A.V. (2021). New RAD51 Inhibitors to Target Homologous Recombination in Human Cells. Genes, 12.","DOI":"10.3390\/genes12060920"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/s41388-021-02162-0","article-title":"An mRNA Expression-Based Signature for Oncogene-Induced Replication-Stress","volume":"41","author":"Bhattacharya","year":"2022","journal-title":"Oncogene"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/j.gastro.2020.09.043","article-title":"Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer","volume":"160","author":"Dreyer","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.ccell.2019.05.006","article-title":"Overcoming Treatment Toxicity through Sequential Therapy","volume":"35","author":"Benada","year":"2019","journal-title":"Cancer Cell"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/2\/1263\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:46:14Z","timestamp":1760103974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/2\/1263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":259,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["ijms25021263"],"URL":"https:\/\/doi.org\/10.3390\/ijms25021263","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]}}}